Published in
American Society of Hematology, Blood Advances, 3(2), p. 210-223, 2018
DOI: 10.1182/bloodadvances.2017011254
Links
Tools
Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists
Journal article published in 2018 by
Christopher T. Petersen,
Mojibade Hassan,
Anna B. Morris 
,
Jasmin Jeffery ,
Kunhee Lee,
Neera Jagirdar,
Ashley D. Staton,
Sunil S. Raikar,
Harold T. Spencer,
Todd Sulchek,
Christopher R. Flowers,
Edmund K. Waller
,
Jasmin Jeffery ,
Kunhee Lee,
Neera Jagirdar,
Ashley D. Staton,
Sunil S. Raikar,
Harold T. Spencer,
Todd Sulchek,
Christopher R. Flowers,
Edmund K. Waller
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points Number of prior chemotherapy cycles in cancer patients correlates with T-cell senescent phenotype and loss of CD27 and CD28 expression. Addition of PI3Kδ inhibitors and VIP antagonists increased ex vivo expansion, in vivo persistence, and anticancer cytotoxicity of T cells.